SI trades 2.4% below Wall Street's consensus target of $19.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SI achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Shoulder Innovations, Inc. (SI) has a Wall Street consensus price target of $19.00, based on estimates from 3 covering analysts. With the stock currently trading at $18.55, this represents a potential upside of +2.4%. The company has a market capitalization of $383M.
Analyst price targets range from a low of $19.00 to a high of $19.00, representing a 0% spread in expectations. The median target of $19.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SI trades at a trailing P/E of -35.7x. Analysts expect EPS to grow +20.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
GMEDGlobus Medical, Inc. | $10.7B | $79.23 | $109.50 | +38.2% | Buy | 16.7x | 36 |
ATECAlphatec Holdings, Inc. | $1.3B | $8.81 | $18.00 | +104.3% | Buy | 27.5x | 18 |
XTNTXtant Medical Holdings, Inc. | $62M | $0.44 | — | — | — | — | — |
NVCRNovoCure Limited | $1.6B | $14.28 | $33.00 | +131.1% | Buy | — | 15 |
ZBHZimmer Biomet Holdings, Inc. | $17.2B | $87.97 | $96.33 | +9.5% | Hold | 10.4x | 42 |
SYKStryker Corporation | $117.9B | $307.80 | $387.46 | +25.9% | Buy | 20.5x | 51 |
JNJJohnson & Johnson | $550.4B | $228.39 | $251.55 | +10.1% | Buy | 19.7x | 40 |
HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
MDTMedtronic plc | $101.9B | $79.34 | $95.80 | +20.7% | Buy | 13.3x | 51 |
BSXBoston Scientific Corporation | $67.3B | $45.29 | $82.90 | +83.0% | Buy | 13.5x | 44 |
Quick answers to the most common questions about buying SI stock.
The consensus price target for SI is $19, close to the current price of $18.55 (2.4% implied move). Based on 3 analyst estimates, the stock appears fairly valued near current levels.
SI has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $19 implies 2.4% upside from current levels.
SI's current price is $18.55 with a consensus target of $19 (2.4% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $19 for SI, while the most conservative target is $19. The consensus of $19 represents the median expectation. These targets typically reflect 12-month expectations.
SI is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SI stock forecast based on 3 Wall Street analysts shows a consensus price target of $19, with estimates ranging from $19 (bear case) to $19 (bull case). The median consensus rating is "Buy".
SI appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $19 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SI analyst price targets range from $19 to $19, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $19 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.